[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-367344-105":59,"doc-detail-367344-en":134},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":127,"head_meta":129,"extra_data":131,"updated_unix":133},105,"en","pan-cancer-analysis-of-co-inhibitory-molecules-revealing-their-potential-prognostic-and-clinical-values-in-immunotherapy","Pan-cancer analysis of co-inhibitory molecules revealing their potential prognostic and clinical values in immunotherapy","","Comprehensive pan-cancer investigation of co-inhibitory molecules assesses expression patterns, correlations, and prognostic implications across multiple cancer types, aiming to address limited responses to existing immune checkpoint inhibitors. Using TCGA, UCSC Xena, TIMER, and CellMiner datasets, the study evaluates links between co-inhibitory molecule expression and immune cell infiltration, with a focused deeper analysis of VISTA. Findings indicate multiple co-inhibitory receptors and ligands associate with prognosis and immune infiltration, while VISTA shows complex relationships with TMB, MSI, stemness, methylation, and drug sensitivity.",{"@graph":69,"@context":126},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/pan-cancer-analysis-of-co-inhibitory-molecules-revealing-their-potential-prognostic-and-clinical-values-in-immunotherapy/367344/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/pan-cancer-analysis-of-co-inhibitory-molecules-revealing-their-potential-prognostic-and-clinical-values-in-immunotherapy/367344.png","ImageObject",300,407,{"name":92,"@type":93},"Mia  ","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-03","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118,122],{"name":109,"@type":110,"acceptedAnswer":111},"What is the main purpose of this pan-cancer analysis?","Question",{"text":112,"@type":113},"To systematically evaluate the expression, correlation, and prognostic value of co-inhibitory molecules across different cancers and assess their relevance to immunotherapy.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which datasets were used to analyze co-inhibitory molecules?",{"text":117,"@type":113},"TCGA, UCSC Xena, TIMER, and CellMiner were used, and immune cell infiltration associations were examined as well.",{"name":119,"@type":110,"acceptedAnswer":120},"What did the results suggest about specific co-inhibitory molecules?",{"text":121,"@type":113},"Differential expression, correlation, and drug sensitivity analyses indicate that multiple listed co-inhibitory receptors/ligands are associated with tumor prognosis and immune cell infiltration.",{"name":123,"@type":110,"acceptedAnswer":124},"Why is VISTA highlighted in the study?",{"text":125,"@type":113},"The analysis indicates VISTA has a complex role, with its expression related to TMB, MSI, cancer cell stemness, DNA/RNA methylation, and drug sensitivity, supporting its potential as a therapeutic target.","https://schema.org",{"og:url":83,"og:type":128,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":130,"canonical":83},"index,follow",{"doc_id":132,"site_id":62},367344,1790196638,{"code":4,"msg":5,"data":135},{"doc_id":132,"user_id":136,"nickname":92,"user_avatar":137,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":143,"language":144,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":145,"faqs":146,"seo_title":147,"seo_description":67,"update_tm":148,"read_time":149,"preview_page_count":19,"preview_urls":150},687207024478,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","TYPE Original Research PUBLISHED 24 March 2025  \nDOI 10.3389/fimmu.2025.1544104  \nOPEN ACCESS  \nEDITED BY  \nJesse Haramati,  \nUniversity of Guadalajara, Mexico  \nREVIEWED BY  \nChristoph Wülﬁng,  \nUniversity of Bristol, United Kingdom Dia Roy,  \nCleveland Clinic, United States  \n*CORRESPONDENCE  \nLei Shi  \n [shil@cqu.edu.cn](shil@cqu.edu.cn)  \n†These authors share ﬁrst authorship  \nRECEIVED 12 December 2024  \nACCEPTED 03 March 2025  \nPUBLISHED 24 March 2025  \nCITATION  \nRen X, Guo A, Geng J, Chen Y, Wang X, Zhou L and Shi L (2025) Pan-cancer analysis of co-inhibitory molecules revealing their potential prognostic and clinical values in immunotherapy. Front. Immunol. 16:1544104 .  \ndoi: 10.3389/fimmu.2025.1544104  \nCOPYRIGHT  \n© 2025 Ren, Guo, Geng, Chen, Wang, Zhou and Shi. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nPan-cancer analysis of coinhibitory molecules revealing their potential prognostic and clinical values in immunotherapy  \nXiaoyu Ren 1†, Anjie Guo 1†, Jiahui Geng 1, Yuling Chen 1, Xue Wang 1, Lian Zhou 2 and Lei Shi 1*  \n1School of Life Sciences, Chongqing University, Chongqing, China, 2 Department of Head&Neck Cancer Center, Chongqing University Cancer Hospital, Chongqing, China  \nBackground: The widespread use of immune checkpoint inhibitors (anti-CTLA4 or PD-1) has opened a new chapter in tumor immunotherapy by providing longterm remission for patients. Unfortunately, however, these agents are not universally available and only a minority of patients respond to them. Therefore, there is an urgent need to develop novel therapeutic strategies targeting other co-inhibitory molecules. However, comprehensive information on the expression and prognostic value of co-inhibitory molecules, including coinhibitory receptors and their ligands, in different cancers is not yet available.  \nMethods: We investigated the expression, correlation, and prognostic value of co-inhibitory molecules in different cancer types based on TCGA, UCSC Xena, TIMER, CellMiner datasets. We also examined the associations between the expression of these molecules and the extent of immune cell inﬁltration. Besides, we conducted a more in-depth study of VISTA.  \nResult: The results of differential expression analysis, correlation analysis, and drug sensitivity analysis suggest that CTLA4, PD-1, TIGIT, LAG3, TIM3, NRP1, VISTA, CD80, CD86, PD-L1, PD-L2, PVR, PVRL2, FGL1, LGALS9, HMGB1, SEMA4A, and VEGFA are associated with tumor prognosis and immune cell inﬁltration. Therefore, we believe that they are hopefully to serve as prognostic biomarkers for certain cancers. In addition, our analysis indicates that VISTA plays a complex role and its expression is related to TMB, MSI, cancer cell stemness, DNA/RNA methylation, and drug sensitivity.  \nConclusions: These co-inhibitory molecules have the potential to serve as prognostic biomarkers and therapeutic targets for a broad spectrum of cancers, given their strong associations with key clinical metrics. Furthermore, the analysis results indicate that VISTA may represent a promising target for cancer therapy.  \nKEYWORDS  \nimmunotherapy, immune checkpoint inhibitors, co-inhibitory molecules, pancancer, biomarkers  \nFrontiers in Immunology 01 [frontiersin.org](frontiersin.org)  \nIntroduction  \nCancer is a serious disease worldwide, and the inefﬁciency of existing therapies such as surgical cutting, radiotherapy, and chemotherapy is a hard nut to crack (1) . Fortunately, cancer treatments are no longer restricted to conventional therapies since the loss of immune control has been proven to be a novel hallmark","cbCaidDDPBH6kLPg","https://ap.wps.com/l/cbCaidDDPBH6kLPg","pdf",23714013,21,"English","# Introduction\n# Background\n# Methods\n## Data sources and analytical approach\n## Focused analysis of VISTA\n# Results\n## Differential expression and correlations\n## Drug sensitivity associations\n# Conclusions\n# Keywords","[{\"question\":\"What is the main purpose of this pan-cancer analysis?\",\"answer\":\"To systematically evaluate the expression, correlation, and prognostic value of co-inhibitory molecules across different cancers and assess their relevance to immunotherapy.\"},{\"question\":\"Which datasets were used to analyze co-inhibitory molecules?\",\"answer\":\"TCGA, UCSC Xena, TIMER, and CellMiner were used, and immune cell infiltration associations were examined as well.\"},{\"question\":\"What did the results suggest about specific co-inhibitory molecules?\",\"answer\":\"Differential expression, correlation, and drug sensitivity analyses indicate that multiple listed co-inhibitory receptors/ligands are associated with tumor prognosis and immune cell infiltration.\"},{\"question\":\"Why is VISTA highlighted in the study?\",\"answer\":\"The analysis indicates VISTA has a complex role, with its expression related to TMB, MSI, cancer cell stemness, DNA/RNA methylation, and drug sensitivity, supporting its potential as a therapeutic target.\"}]","Pan-cancer analysis of co-inhibitory molecules revealing their potential prognostic and clinical values in immunotherapy | PDF",1790170384,53,[151,155,159,163],{"page_no":8,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3552e174be1810e4bdccdb6b53865b88.webp",983,1389,{"page_no":14,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3177bf384f29f10923c6d179ea2528a3.webp",982,1388,{"page_no":81,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3d3deca99493c9c4d646040487ffcca2.webp",981,1386,{"page_no":19,"url":164,"width":165,"height":166},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8d534ecaf8848fe43c0567f008782d4d.webp",980,1385]